Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Cumberland Pharmaceuticals Inc
Research & Development
Cumberland Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
Research & Development
-$5.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-2%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Cumberland Pharmaceuticals Inc
Glance View
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. The company is headquartered in Nashville, Tennessee and currently employs 83 full-time employees. The company went IPO on 2009-08-11. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.
See Also
What is Cumberland Pharmaceuticals Inc's Research & Development?
Research & Development
-5.3m
USD
Based on the financial report for Sep 30, 2025, Cumberland Pharmaceuticals Inc's Research & Development amounts to -5.3m USD.
What is Cumberland Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-2%
Over the last year, the Research & Development growth was -11%. The average annual Research & Development growth rates for Cumberland Pharmaceuticals Inc have been 8% over the past three years , 4% over the past five years , and -2% over the past ten years .
